Moderna Inc [NASDAQ: MRNA] stock went on an upward path that rose over 2.79% on Monday, amounting to a one-week price increase of more than 7.66%.
Over the last 12 months, MRNA stock dropped by -43.04%. The one-year Moderna Inc stock forecast points to a potential upside of 40.07. The average equity rating for MRNA stock is currently 2.57, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $16.90 billion, with 385.00 million shares outstanding and 343.15 million shares in the current float. Compared to the average trading volume of 7.00M shares, MRNA stock reached a trading volume of 6780459 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Moderna Inc [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $73.85 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.57. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Berenberg have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 19, 2024. The new note on the price target was released on November 18, 2024, representing the official price target for Moderna Inc stock. Previously, the target price had yet another raise to $40, while Wolfe Research analysts kept a Underperform rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc is set at 2.82, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 3.33. The Price to Book ratio for the last quarter was 1.43, with the Price to Cash per share for the same quarter was set at 17.98.
MRNA Stock Performance Analysis:
Moderna Inc [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.66. With this latest performance, MRNA shares dropped by -18.58% in over the last four-week period, additionally sinking by -70.06% over the last 6 months – not to mention a drop of -43.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 45.18, with the RSI for the last a single of trading hit 52.70, and the three-weeks RSI is set at 40.38 for Moderna Inc [MRNA]. The present Moving Average for the last 50 days of trading for this stock 52.39, while it was recorded at 43.28 for the last single week of trading, and 94.99 for the last 200 days.
Insight into Moderna Inc Fundamentals:
Moderna Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.20 and a Current Ratio set at 4.39.
Moderna Inc [MRNA] Institutonal Ownership Details
There are presently around $71.60%, or 79.14%% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 43.45 million shares, which is approximately 11.3741%. VANGUARD GROUP INC, holding 39.56 million shares of the stock with an approximate value of $$4.7 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $$3.04 billion in MRNA stock with ownership which is approximately 6.6917%.
